Literature DB >> 22053897

Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study.

Antonio Ciudad1, Enrique Álvarez, Miquel Roca, Enrique Baca, Luis Caballero, Pepa García de Polavieja, Marta Casillas, Amparo Valladares, Inmaculada Gilaberte.   

Abstract

OBJECTIVE: The goal of treating major depressive disorder (MDD) should be not only achieving remission in a particular episode but also avoiding relapses and attaining long-term recovery. The current study was designed to evaluate whether response and remission achieved within the first 6 weeks of antidepressant treatment are associated with a 12-month good outcome (achieving remission by 6 months and remaining in remission until the end of follow-up).
METHOD: This prospective, longitudinal, multicenter study included adult outpatients who had a DSM-IV diagnosis of MDD, baseline scores ≥ 15 on the 17-item Hamilton Depression Rating Scale (HDRS(17)), Clinical Global Impressions-Severity of Illness scores ≥ 4, and a minimum remission period of 12 weeks between the index episode and the immediately prior episode (or who were in their first MDD episode). The primary efficacy measure was early response (a 50% decrease from baseline in HDRS(17) score by week 6). The secondary efficacy measure was early remission (HDRS(17) score ≤ 7 by week 6).
RESULTS: Among the total of 930 patients included from December 2006 to June 2007, 38.2% showed early response, and 20.5% showed early remission. Of the early responders, 76.1% had a 12-month good outcome as compared to 81.1% of early remitters. Logistic regression showed that factors associated with a good outcome included early response (odds ratio [OR] = 4.14), being employed, and the absence of physical comorbidities. Early remission was also strongly associated with a good outcome (OR = 4.72).
CONCLUSIONS: Either response or remission achieved by week 6 is the strongest prognostic factor for the 12-month good outcome of an episode of MDD. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22053897     DOI: 10.4088/JCP.10m06314

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Bouncing back: remission from depression in a 12-year panel study of a representative Canadian community sample.

Authors:  Esme Fuller-Thomson; Marla Battiston; Tahany M Gadalla; Sarah Brennenstuhl
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-09       Impact factor: 4.328

Review 2.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

3.  The effectiveness of antidepressant monotherapy in a naturalistic outpatient setting.

Authors:  Tih-Shih Lee; Pryseley Nkouibert Assam; Kenneth R Gersing; Edwin Chan; Bruce M Burchett; Kang Sim; Lei Feng; K Ranga Krishnan; A John Rush
Journal:  Prim Care Companion CNS Disord       Date:  2012-10-04

4.  Agomelatine as monotherapy for major depression: an outpatient, open-label study.

Authors:  Jan Pecenak; Vladimir Novotny
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-22       Impact factor: 2.570

5.  Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.

Authors:  Leslie Citrome; Carl P Gommoll; Xiongwen Tang; Rene Nunez; Maju Mathews
Journal:  Int Clin Psychopharmacol       Date:  2015-03       Impact factor: 1.659

6.  Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study.

Authors:  Alonso Montoya; Jeremie Lebrec; Karen Mary Keane; Irene Fregenal; Antonio Ciudad; Ángel Moríñigo; Luis Agüera-Ortiz; Irene Romera; Inmaculada Gilaberte; Mark Zimmerman
Journal:  BMC Psychiatry       Date:  2016-10-19       Impact factor: 3.630

7.  Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis.

Authors:  Irene Romera; Víctor Pérez; Antonio Ciudad; Luis Caballero; Miguel Roca; Pepa Polavieja; Inmaculada Gilaberte
Journal:  BMC Psychiatry       Date:  2013-02-11       Impact factor: 3.630

8.  Remission from Depression among Adults with Arthritis: A 12-Year Followup of a Population-Based Study.

Authors:  Esme Fuller-Thomson; Marla Battiston; Tahany M Gadalla; Yael Shaked; Ferrah Raza
Journal:  Depress Res Treat       Date:  2014-01-27

9.  Clinical predictors associated with full remission versus episode of major depressive disorder outpatients: the experience at a teaching hospital in Taiwan.

Authors:  Mei-Yu Yeh; Yu Lee; Su-Ching Sung; Tao-Hsin Tung
Journal:  BMC Psychiatry       Date:  2014-09-24       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.